Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 14, 2026
Modular Medical (MODD) Drops -57% in 30 Days as Commercial Momentum Slows

Modular Medical (MODD) Drops -57% in 30 Days as Commercial Momentum Slows

Key Takeaways

  • Modular Medical (MODD) closed at $1.87 on August 13, 2026, down approximately 57% from the $4.31 closing price recorded 30 calendar days earlier on July 14, 2026.
  • The decline has pushed the stock toward the lower end of its 52-week range of $1.74–$30.00 and well below its 50-day moving average near $3.64.
  • The sell-off followed a period of commercial-launch momentum, including FDA 510(k) clearance for the Pivot tubeless insulin patch pump in April 2026, that had lifted shares earlier in the year.
  • Modular Medical remains essentially pre-revenue, with a trailing twelve-month net loss of about $28.2 million and roughly $6.9 million in cash as of its most recent quarter, keeping funding and dilution risk in focus.
  • Heavy volume on August 13 and an increase in short interest to approximately 214,000 shares reflect fragile near-term sentiment.

Company Overview and Market Position

Modular Medical, Inc. (NASDAQ: MODD) is a San Diego-based medical device company focused on insulin delivery technology. Its flagship product, the Pivot tubeless insulin patch pump, is designed for adults with type 1 and type 2 diabetes who use multiple daily injections. The company positions Pivot around simplicity and accessibility, targeting a large population of insulin users who have not adopted traditional pumps. After receiving FDA 510(k) clearance in April 2026, Modular Medical transitioned from a development-stage business into an early commercial-stage company, and investors now follow the stock primarily for launch execution, payer traction, manufacturing scale-up, and cash runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the 30 calendar days ended August 13, 2026, MODD declined from a closing price of $4.31 on July 14 to $1.87, a drop of roughly 56.6%. The move was not a single-day event: the stock recorded sharp single-session declines on July 16 (-22.7%), July 24 (-17.4%), and August 13 (-9.7%), with the August 13 decline occurring on volume of about 1.6 million shares compared with an average closer to 129,000.

The weakness extends beyond the 30-day window. Over the trailing three months, MODD has fallen approximately 44.5% from a closing price of $3.37 on May 15. Year to date, the stock is down about 83% from $10.92 at the end of 2025, underscoring a sustained downtrend despite positive product-related milestones. From what I see, this kind of sustained pressure often warrants a closer look at volume patterns and short interest trends.

What Drove the Stock in the Last 30 Days

Early in the period, MODD benefited from a series of verified commercial updates, including the start of Pivot shipments to endocrinology practices, initial patient insulin deliveries, a pilot program with IMO Health to identify eligible patients through electronic health records, and the formation of a Pivot Innovation Council. Those announcements supported a late-June advance, with the stock trading as high as $5.81 intraday on June 26.

That optimism faded in mid-July as investors refocused on fundamentals. Modular Medical is still generating essentially no revenue while posting a trailing twelve-month net loss near $28.2 million. With about $6.9 million in cash as of its most recent quarter and negative operating cash flow, the company faces recurring questions about future capital raises and shareholder dilution. A $3.4 million registered direct offering priced at $4.50 per share in April 2026, along with earlier financing activity, kept those concerns in the foreground. The resulting selling pressure appeared amplified by risk-off sentiment in micro-cap healthcare names, with down days occurring on above-average volume and short interest rising from roughly 162,000 to about 214,000 shares.

What Drove Performance Over the Last Quarter

The broader three-month decline reflects a market repricing of an early commercial-stage medical device company that has achieved regulatory clearance but has yet to demonstrate revenue or a clear path to profitability. Positive developments included FDA clearance for Pivot, the first commercial shipments, manufacturing preparations, and new clinical-commercial partnerships. These were offset by ongoing cash burn, a 1-for-30 reverse stock split completed at the end of March 2026, a workforce reduction announced in March 2026 to lower operating expenses, and dilutive financing transactions. The result was a quarter in which improving commercialization news was outweighed by financing overhang, execution uncertainty, and weak sentiment toward pre-revenue small-cap medical technology stocks. One thing that stands out is how quickly sentiment can shift once execution risks come back into focus.

What Investors Should Watch Next

The most important factors for MODD going forward include the pace of Pivot commercial adoption, physician training, patient onboarding, and early repeat ordering. Reimbursement and payer coverage discussions will be critical, as will results from the IMO Health electronic health record pilot. Investors should also monitor the FDA’s response to the software enhancements the company has submitted for Pivot, along with any updates on manufacturing capacity and gross margin trajectory. The next quarterly earnings release and management commentary on cash runway will be closely watched, particularly for signals about future financing needs. Finally, Nasdaq listing compliance and the stock’s ability to hold above the $1.00 minimum bid threshold remain relevant risk factors amid a competitive insulin pump market. I’m watching this closely for any signs of stabilization in the coming weeks.

Exploring Quantitative Trading Tools

In my research process, I sometimes review Tickeron’s Trending AI Robots page to see which automated strategies are gaining attention across different market conditions. It offers a practical way to compare trading styles and timeframes without relying on a single approach, which can add useful context when evaluating names like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: MODD

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


MODD in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 08, 2026

MODD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 44 of 48 cases where MODD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where MODD advanced for three days, in 173 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The 10-day RSI Indicator for MODD moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MODD as a result. In 88 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for MODD turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

MODD moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MODD crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for MODD entered a downward trend on August 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.666) is normal, around the industry mean (10.643). P/E Ratio (0.000) is within average values for comparable stocks, (100.549). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.062). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (39.536).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. MODD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.55B. The market cap for tickers in the group ranges from 837 to 177.55B. ABT holds the highest valuation in this group at 177.55B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -1%. AEMD experienced the highest price growth at 312%, while FEED experienced the biggest fall at -71%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 38%. For the same stocks of the Industry, the average monthly volume growth was 69% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 74
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 95
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
MODD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Profile
Details
Industry
N/A
Address
10470 Thornmint Road
Phone
+1 858 800-3500
Employees
51
Web
https://www.modular-medical.com
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.